Clinical trials: Parkinson's
Parkinson Disease
Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa
The survey is conducted to collect safety and effectiveness information in Parkinson's Disease patients treated with Pramipexole without concomitant L-Dopa supplementation in the daily clinical settings in Japan.
- Trial name
- NCT00613301
- Where
- 119 sites in Japan
- Volunteers
- 416 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
The Effects of Dual Task Training in Individuals With Parkinson's Disease
The primary aim of the proposed project is to characterize dual tasking (DT) deficits to improve motor, cognitive, and quality of life outcomes in individuals with Parkinson's disease (PD).
- Trial name
- NCT02538029
- Testing
- Dual Task Group, Single Task Group
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- The Cleveland Clinic
Parkinson's Disease
The Effect of Donepezil on Gait and Balance in Parkinson's Disease
This study involves Parkinson's disease (PD). Symptoms include slow movement, tremor, and muscle rigidity. Current medications for the treatment of PD do not improve gait and balance difficulties in individuals with PD.
- Trial name
- NCT01521117
- Testing
- Donepezil
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Oregon Health and Science University
Parkinson's Disease, Helicobacter Infections
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.
- Conditions
- Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
- Trial name
- NCT00664209
- Testing
- clartihromycin, amoxicillin, and omeprazole
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
REM Behavior Disorder, Parkinsonism
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
Parkinson's disease (PD) is the second most common neurodegenerative disorder of the elderly that affects a million patients in US. Sleep dysfunction impacts up to 90% of PD patients.
- Trial name
- NCT00745030
- Testing
- Rozerem
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Idiopathic Parkinson's Disease
Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
The primary objective of this study is to evaluate the perception of pain associated with Parkinson´s Disease in patients who receive Neupro® for the first time.
- Trial name
- NEUPAD (NCT01606670)
- Where
- 27 sites in Austria, Germany
- Volunteers
- 93 people
- Sponsor
- UCB Pharma GmbH
Parkinson Disease
Deep Brain Stimulation (DBS) Frequency Effects on Gait in Parkinson's Disease(PD)
In this study the investigators will evaluate the effect of both low and high frequency Deep Brain stimulation of the subthalamic nucleus (STN) in Parkinson's patients who have noted a change in their walking.
- Trial name
- NCT00993291
- Testing
- Frequency change to 60 Hz, Frequency change to 130 Hz
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University
Parkinson Disease
Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole
The survey is conducted to collect safety and effectiveness information on the use of Pramipexole for long time of period in daily clinical settings in Japan.
- Trial name
- NCT00615914
- Where
- 273 sites in Japan
- Volunteers
- 1,645 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease, Sleep Disorder; Excessive Somnolence
Light Therapy Treatment in Parkinson's Disease Patients With Daytime Somnolence
Study objectives are to determine the efficacy, safety and tolerability of bright light treatment in Parkinson's Disease (PD) patients with daytime sleepiness.
- Trial name
- NCT01338649
- Testing
- Bright Light Treatment (Sun Ray Sunbox SB-558), Dim red light (Sun Ray Sunbox SB-558)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Parkinson's Disease
A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients
The primary objective of this study is to investigate safety of SPM 962 in advanced PD patients in a multi-center, open-label, non-controlled study following once-daily multiple transdermal doses of SPM962 within a range of 4.5…
- Trial name
- NCT01631812
- Testing
- SPM 962
- Where
- 7 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinson's Disease
Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations
A 48-month open label multi-centered extension study to evaluate the long-term safety, tolerability and efficacy of E2007 in patients with Parkinson's Disease with "wearing off" motor fluctuations and "on" period Dyskinesias.
- Trial name
- NCT01634360
- Testing
- Perampanel
- Volunteers
- 185 people
- Sponsor
- Eisai Inc.
Parkinson's Disease With Dementia
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease
The project will investigate the effect of pharmacological and electric modulation of N-methyl-D-aspartate (NMDA) pathway on the cognitive flexibility and volitional movement preparation in patients with Parkinson's disease (PD).
- Trial name
- NCT01785628
- Testing
- Sarcosine Capsule
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Parkinson's Disease
NET-PD LS-1 Creatine in Parkinson's Disease
The purpose of this trial is to determine if the nutritional supplement creatine slows the progression of Parkinson's disease over time.
- Trial name
- NCT00449865
- Testing
- creatine
- Where
- 50 sites in United States, Canada
- Volunteers
- 1,741 people
- Sponsor
- University of Rochester
Parkinson's Disease
A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients
Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease patients who are not concomitantly treated with L-dopa will be investigated with a doses.
- Trial name
- NCT01628965
- Testing
- SPM 962
- Where
- 7 sites in Japan
- Volunteers
- 143 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Idiopathic Parkinson's Disease
Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch
The study intends to collect data on gastrointestinal symptoms (swallowing disorders, heartburn, feeling of fullness, nausea, vomiting, abdominal pain, diarrhea) and on patient satisfaction under everyday practice conditions…
- Trial name
- NON-GI (NCT01159691)
- Where
- 21 sites in Germany
- Volunteers
- 76 people
- Sponsor
- UCB Pharma GmbH
Parkinson's Disease Psychosis
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
- Trial name
- NCT01518309
- Testing
- pimavanserin tartrate (ACP-103)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson Disease, Impaired Cognition
Cognitive Training in Parkinson Study
This study evaluates the efficacy of an eight-week online cognitive training program on objective and subjective cognitive functions in Parkinson's disease.
- Conditions
- Parkinson Disease, Impaired Cognition, Alteration in Cognition
- Trial name
- cogtips (NCT02920632)
- Testing
- Online cognitive training 1, Online cognitive training 2
- Where
- Netherlands
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Parkinson's Disease
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in…
- Trial name
- NCT01631825
- Testing
- SPM 962
- Where
- 8 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinson Disease
Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials
An observational study to characterize and compare long-term clinical outcomes data collected remotely through periodic tele-visits, interactive smartphone app sessions, and web-based surveys in individuals with Parkinson's…
- Trial name
- AT-HOME PD (NCT03538262)
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Massachusetts General Hospital
Parkinson's Disease, Hyperprolactinemia
The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
To assess the association between cabergoline and other dopamine agonists (DAs), and symptomatic, diagnosed serious cardiopulmonary disorders, including: 1. Cardiac valve regurgitation 2.
- Trial name
- NCT01052948
- Testing
- Retrospective study-
- Volunteers
- 86,939 people
- Sponsor
- Pfizer